Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

menarini international o.l.s.a. - medoksomilolmesartanat - filmsko obložena tableta - medoksomilolmesartanat 40 mg / 1 tableta - medoksomilolmesartanat

Evropska unija - slovenščina - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - ceftolozane sulfat, tazobactam natrijev - bakterijske okužbe - antibacterials za sistemsko uporabo, - zerbaxa is indicated for the treatment of the following infections in adults:complicated intra abdominal infections;acute pyelonephritis;complicated urinary tract infections;hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap). upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

amlodipin; lizinopril - tableta - amlodipin 10 mg / 1 tableta  lizinopril20 mg / 1 tableta; lizinopril 20 mg / 1 tableta - lizinopril in amlodipin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

amlodipin; lizinopril - tableta - amlodipin 10 mg / 1 tableta  lizinopril20 mg / 1 tableta; lizinopril 20 mg / 1 tableta - lizinopril in amlodipin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

amlodipin; lizinopril - tableta - amlodipin 10 mg / 1 tableta  lizinopril20 mg / 1 tableta; lizinopril 20 mg / 1 tableta - lizinopril in amlodipin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

amlodipin; lizinopril - tableta - amlodipin 5 mg / 1 tableta  lizinopril20 mg / 1 tableta; lizinopril 20 mg / 1 tableta - lizinopril in amlodipin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

amlodipin; lizinopril - tableta - amlodipin 5 mg / 1 tableta  lizinopril20 mg / 1 tableta; lizinopril 20 mg / 1 tableta - lizinopril in amlodipin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

amlodipin; lizinopril - tableta - amlodipin 5 mg / 1 tableta  lizinopril20 mg / 1 tableta; lizinopril 20 mg / 1 tableta - lizinopril in amlodipin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

amlodipin; lizinopril - tableta - amlodipin 5 mg / 1 tableta  lizinopril10 mg / 1 tableta; lizinopril 10 mg / 1 tableta - lizinopril in amlodipin

Evropska unija - slovenščina - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastična sredstva - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq kot monotherapy je indiciran za zdravljenje odraslih bolnikov z lokalno napredno ali metastatskim nsclc po predhodno kemoterapijo. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq kot monotherapy je indiciran za zdravljenje odraslih bolnikov z lokalno napredno ali metastatskim nsclc po predhodno kemoterapijo. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.